CardioMEMS Implantation Using Gadolinium-based Contrast Agent: A Case Report
نویسندگان
چکیده
منابع مشابه
No Association between Gadolinium-Based Contrast Agents and Development of Nephrogenic Systemic Fibrosis: a Case Study
Nephrogenic systemic fibrosis (NSF), previously known as nephrogenic fibrosing dermopathy, is an emerging systemic fibrosing disorder that develops in the setting of renal insufficiency. Nephrogenic fibrosing dermopathy (NFD) is a fibrosing condition of the skin which shows an increased number of dendritic cells, fibroblasts and thickened collagen fibers resembling scleromyxedema. It is charact...
متن کاملA Novel Gadolinium-Based Contrast Agent Targeted to Cathepsin-D
slice images of Gd-DTPA, Gd-DOTACAT and 10% BSA at 37oC at 9.4T. Figure 2. Relaxation rate (R1 = 1/T1) as a function of concentration. Gd-DOTACAT has a greater relaxivity 6.9 (mM s) than clinically used Gd-DTPA (Magnevist®) of 3.2 (mM s). Figure 3. Signal intensity plots from 3 regions of interest: brain tissue, cerebral and non-cerebral blood vessels. There was an increase in signal intensity ...
متن کاملGadolinium-DTPA: A New Contrast Agent
Gadolinium (Gd)-DTPA-dimeglumine (tradename: Magnevist?) is the first commercially available contrast agent for magnetic resonance tomography (MRT). As a result of the very favourable results from preclinical and clinical investigations Magnevist? was granted a product license for cranial and spinal MRT in the Federal Republic of Germany in early February this year. Magnevist? is a paramagnetic...
متن کاملGadolinium as a contrast agent for NMR.
Gadolinium chloride (GdCl3) was studied as a contrast agent for nuclear magnetic resonance. This rare-earth element dramatically alters proton resonance (paramagnetic moment = 10.8 Bohr magnetons). Acute toxicity was determined by intravenous injections in mice; mean lethal dose was 100-200 mg of GdCl3 . 6 H2O/kg. Changes in T1 of plasma, kidney, liver, and brain of mice and rats were measured ...
متن کاملGadolinium-Based Contrast Agent Accumulation and Toxicity: An Update.
In current practice, gadolinium-based contrast agents have been considered safe when used at clinically recommended doses in patients without severe renal insufficiency. The causal relationship between gadolinium-based contrast agents and nephrogenic systemic fibrosis in patients with renal insufficiency resulted in new policies regarding the administration of these agents. After an effective s...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cardiac Failure Review
سال: 2021
ISSN: 2057-7559,2057-7540
DOI: 10.15420/cfr.2021.03